Publication date: May 06, 2024
The long-lasting persistence of autoantibodies stands as one of the hypotheses explaining the multisystemic manifestations seen in individuals with post-COVID-19 condition. The current review offers restricted insights into the persistence of autoantibodies in plasma/serum in people with post-COVID symptoms. PubMed/MEDLINE, CINAHL, EMBASE, and Web of Science databases, as well as on medRxiv and bioRxiv preprint servers were searched up to January 5, 2024. Papers investigating the presence of autoantibodies in plasma/serum samples in people with post-COVID symptoms were included. The Newcastle-Ottawa Scale (NOS) was used to assess methodological quality. From 162 identified records, five articles met all inclusion criteria; four studies included infected controls with no post-COVID symptoms whereas all five studies included non-infected controls (410 COVID-19 survivors with post-COVID symptoms, 223 COVID-19 survivors with no post-COVID symptoms as controls and 266 non-infected healthy controls). Four studies concluded that the presence of autoantibodies had a potential (but small) role in post-COVID-19 condition whereas one study concluded that autoantibodies were not associated. Quality assessment showed all studies had high methodological quality. Although evidence suggests that persistent autoantibodies can be associated with post-COVID symptoms, the clinical relevance of their presence seems modest at this stage. Current results highlight further research to clarify the role of autoantibodies in the development of post-COVID symptoms, guiding the development of tailored diagnostic and treatment approaches to enhance patient outcomes. https://osf. io/vqz28.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | IDO | quality |
| drug | DRUGBANK | Methionine |
| disease | MESH | clinical relevance |
| disease | MESH | Long Covid |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | Hypertension |
| disease | MESH | cognitive dysfunction |
| disease | MESH | chest pain |
| disease | MESH | presyncope |
| disease | MESH | sleep disorders |
| disease | MESH | irregular menstruation |
| disease | MESH | dysbiosis |
| disease | MESH | autoimmunity |
| disease | MESH | inflammation |
| drug | DRUGBANK | Angiotensin II |
| drug | DRUGBANK | Cardiolipin |
| disease | VO | Glycoprotein |
| drug | DRUGBANK | Thyroglobulin |
| disease | MESH | syndrome |
| disease | VO | population |
| disease | IDO | intervention |
| disease | VO | time |
| disease | IDO | assay |
| disease | IDO | process |
| disease | IDO | country |
| disease | MESH | sequelae |
| disease | MESH | infection |
| disease | IDO | acute infection |
| disease | VO | Anas |
| disease | MESH | autoimmune diseases |
| drug | DRUGBANK | Choline |
| disease | VO | Canada |
| disease | VO | protocol |